“…FNA itself also has a certain risk of adverse events. A meta‐analysis of 40 articles evaluating morbidity and mortality associated with EUS‐FNA for PCL showed overall morbidity of 2.66% (95% CI, 1.84–3.62) and associated mortality of 0.19% (95% CI, 0.09–0.32) and also showed common post‐procedure adverse events including pancreatitis (0.92%, 95% CI, 0.63–1.28), hemorrhage (0.69%, 95% CI: 0.42–1.02), pain (0.49%, 95% CI: 0.27–0.79%), infection (0.44%, 95% CI: 0.27–0.66), desaturation (0.23%, 95% CI: 0.12–0.38) and perforation (0.21%, 95% CI: 0.11–0.36%) . The overall adverse event rate was relatively low; however, most studies did not include long term follow‐up data.…”